Indium (111in)-Dtpa Curium Netherlands Bv (Pentetic Acid, Indium (111in) Pentetate)

Indium-111 pentetate, the active ingredient in Indium (111in)-Dtpa Curium Netherlands Bv, is a radiopharmaceutical presented as a sterile solution for intrathecal use. It is employed to image cerebrospinal fluid pathways and to locate cerebrospinal fluid leaks in patients undergoing diagnostic evaluation.

GNH USA supplies Indium (111in)-Dtpa Curium Netherlands Bv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Indium (111in)-Dtpa is a radiopharmaceutical used in diagnostic imaging of the cerebrospinal fluid system and related leak detection. - Cerebrospinal fluid imaging: provides high‑resolution visualization of CSF distribution for diagnostic assessment. - Detection of CSF leaks: helps locate spinal or cranial cerebrospinal fluid leaks. - Post‑surgical CSF flow evaluation: assesses CSF dynamics after neurosurgical procedures.

Adverse reactions may occur following intrathecal administration of Indium (111in)-Dtpa.

Common Side Effects: - Headache: mild to moderate discomfort after injection. - Nausea: transient feeling of queasiness. - Transient pain at injection site: brief discomfort at lumbar puncture site. - Low‑grade fever: mild temperature rise within 24 hours. - Allergic rash: skin redness or urticaria.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis requiring emergency care. - Hypotension: notable drop in blood pressure post‑procedure. - Seizure activity: rare neurologic event. - Radiation‑induced tissue injury: uncommon but possible with high cumulative exposure.

Prior to use, clinicians should observe specific safety measures to minimize risk. - Verify patient identity and indication: ensure correct procedure and diagnosis. - Maintain sterile technique: use aseptic conditions for intrathecal injection. - Assess for DTPA allergy: inquire about prior hypersensitivity to chelating agents. - Monitor radiation exposure: limit cumulative dose in line with regulatory guidelines. - Use in pregnancy only if essential: weigh diagnostic benefit against fetal radiation risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before administration.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may cause overlapping radiation fields and inaccurate imaging. - High‑dose chelating agents (e.g., EDTA): can displace Indium‑111 from the DTPA complex.

Moderate Interactions (Monitor Closely): - Intrathecal contrast media: may alter distribution of the tracer. - Drugs affecting CSF flow (e.g., acetazolamide): could modify tracer kinetics. - Anticoagulants: increase risk of bleeding at lumbar puncture site.